Hyseq Agrees to Purchase Variagenics
From Bloomberg News
Hyseq Inc. of Sunnyvale agreed to buy Variagenics Inc. for about $55.9 million in stock to accelerate development of a drug to dissolve blood clots and develop other products.
Hyseq would exchange about 1.65 shares for each Variagenics share, the companies said. That values Variagenics, based in Cambridge, Mass., at $2.22 a share, more than double Friday’s closing price of 96 cents.
Shares of Hyseq fell 27 cents to $1.08 on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
